Pembrolizumab Mechanism of Action: How Pembrolizumab Works | Elicit
Pembrolizumab Mechanism of Action
How Pembrolizumab (Keytruda) Works: PD-1 checkpoint blockade that prevents PD-L1/PD-L2 from inactivating T cells.
Last updated: March 2026
Quick Summary
Pembrolizumab (Keytruda) is a humanized monoclonal antibody in the cancer immunotherapy class that targets PD-1 on lymphocytes. By binding PD-1 and blocking PD-L1/PD-L2 interaction, it helps restore T-cell response and can improve T-cell–mediated tumor killing.
Properties
| Details | |
|---|---|
| Generic Name | Pembrolizumab |
| Brand Names | Keytruda |
| Drug Class | Immune checkpoint inhibitor (anti–PD-1) monoclonal antibody |
| Primary Target | Programmed cell death protein 1 (PD-1) (PDCD1) |
| Approved Indications | Multiple solid tumors and hematologic malignancies (tumor-agnostic: MSI-H/dMMR and TMB-H cancers), including melanoma, NSCLC, HNSCC, classical Hodgkin lymphoma, urothelial carcinoma, gastric/GEJ adenocarcinoma, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, RCC, endometrial carcinoma, CRC, biliary tract cancer, TNBC, and others |
| Key Effect | Restores T-cell immune response by blocking PD-1 interactions with PD-L1/PD-L2 |
Development History
Pembrolizumab originated at Organon BioSciences in Oss, Netherlands, was advanced through Schering-Plough, and entered Merck's portfolio via the 2009 acquisition of Schering-Plough, where it carried the codes MK-3475 and the early INN lambrolizumab. The molecule is a humanized IgG4-kappa monoclonal antibody against the programmed death receptor-1 (PD-1) developed to block PD-1 engagement by PD-L1 and PD-L2 and restore exhausted T-cell antitumor activity.
The first registrational data came from the Phase 1 KEYNOTE-001 adaptive study (NCT01295827), which grew through eight protocol amendments into the largest Phase 1 program in oncology history and co-developed the 22C3 pharmDx PD-L1 companion diagnostic. In the ipilimumab-refractory melanoma cohort, the anti-PD-1 antibody produced an objective response rate of roughly 24% with durable responses, supporting accelerated filing. On September 4, 2014, the FDA granted accelerated approval to Keytruda for advanced or unresectable melanoma in patients progressing after ipilimumab, and a BRAF inhibitor for BRAF V600 mutation-positive disease.
The first registrational data came from the Phase 1 KEYNOTE-001 adaptive study (NCT01295827), which grew through eight protocol amendments into the largest Phase 1 program in oncology history. In the ipilimumab-refractory melanoma cohort, the anti-PD-1 antibody produced an objective response rate of roughly 24% with durable responses, supporting accelerated filing.
Detailed Mechanism of Action
Antibody architecture and pharmacokinetics. Pembrolizumab is a humanized IgG4 monoclonal antibody with a crystallographically resolved full-length structure. After intravenous infusion, pembrolizumab distributes systemically with access to tumor-draining lymph nodes, intratumoral stroma, and peripheral blood lymphocyte pools. Pharmacokinetically, it exhibits a terminal half-life of approximately 26 days.
PD-1 target binding. Pembrolizumab's primary molecular target is PD-1, an inhibitory checkpoint receptor expressed on activated T cells, NK cells, and antigen-presenting cells.
Downstream signaling consequences. Under physiological conditions, PD-1 ligation by PD-L1 or PD-L2 phosphorylates inhibitory ITIM and ITSM motifs in its cytoplasmic tail.
T cell reinvigoration. Pembrolizumab interrupts all of these inhibitory nodes simultaneously by physically excluding PD-L1/PD-L2 from the PD-1 binding site.
Clinical translation. This molecular cascade maps onto measurable antitumor immunity. Pembrolizumab shows tumor-agnostic activity in tumors with mismatch-repair deficiency.
Clinical Relevance
Approved Indications
- MSI-H/dMMR solid tumors (tissue-agnostic): Approval for adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment.
- Unresectable or metastatic melanoma: Pembrolizumab received FDA approval based on significant improvement in overall survival versus ipilimumab.
- Metastatic NSCLC: FDA approval for first-line use in patients with high PD-L1 expression.
Key Drug Interactions (Mechanism-Based)
- Corticosteroids used for immune-related adverse events require prompt initiation, ensuring careful management of treatment responses.
- Antibiotics can reduce immunotherapy efficacy, indicating a relationship between microbiome disruption and outcome in pembrolizumab-treated NSCLC patients.
Immune-Mediated Adverse Reactions
- Common immune-mediated adverse reactions include pneumonitis, colitis, hepatitis, and thyroid disorders.
Emerging Indications
Neurology
- Recurrent Glioblastoma: Exploits the PD-1/PD-L1 axis for T-cell infiltration suppression.
Oncology
- Advanced Biliary Tract Cancer: Ongoing phase 3 trial testing pembrolizumab's efficacy combined with chemotherapy.
Clinical Trials of Pembrolizumab
| Trial Name | Phase | Design | N Enrolled | Intervention | Indication | Primary Endpoint | Key Result | Status |
|---|---|---|---|---|---|---|---|---|
| KEYNOTE-A39 | 3 | Randomized, open-label trial | 886 | Enfortumab vedotin plus pembrolizumab vs. chemotherapy | Urothelial | Overall survival (OS) | Combination nearly doubled median overall survival (OS) to 31.5 months. | Ongoing |
| KEYNOTE-868 | 3 | Randomized, blinded, placebo-controlled trial | 819 | Pembrolizumab plus standard chemotherapy | Endometrial | Progression-free survival (PFS) | Resulted in statistically significant improvement in PFS compared to chemotherapy alone. | Ongoing |
Pembrolizumab Competitive Landscape
| Drug Class | Representative Drug(s) | Primary Molecular Target | Mechanism of Action | Key Efficacy Outcomes | Route & Dosing | Safety / Risk Profile | Key Limitations |
|---|---|---|---|---|---|---|---|
| PD-1 inhibitors | Pembrolizumab, Nivolumab | PD-1 (Programmed death receptor-1) | Binds to PD-1 on T-cells, removing the inhibition of the anti-tumor immune response. | Superior overall survival (OS) compared to anti-PD-L1 therapy. | IV infusion; dosing varies | Severe immune-mediated adverse reactions can occur. | Efficacy may depend on PD-L1 expression levels. |
| PD-L1 inhibitors | Atezolizumab, Durvalumab, Avelumab | PD-L1 (Programmed death-ligand 1) | Blocks PD-L1 interaction with PD-1 and CD80 receptors. | Efficacy may be lower than PD-1 inhibitors. | IV infusion; dosing varies | Same as PD-1 inhibitors. | Limited benefit in low PD-L1 expressers. |
| CTLA-4 inhibitors | Ipilimumab | CTLA-4 | Blocks CTLA-4 on T-cells, enhancing activation and proliferation. | Monotherapy response rates lower compared to PD-1 inhibitors. | IV infusion; specific dosing regimen | Higher incidence of adverse events than PD-1/L1 inhibitors. | Response rates lower in advanced melanoma. |
| LAG-3 inhibitors | Relatlimab | LAG-3 | Reduces immune inhibition, promoting T-cell proliferation. | Improved PFS in combination with PD-1 inhibitors. | IV infusion in fixed-dose combination with nivolumab. | Manageable safety profile; lower than PD-1/CTLA-4 combination. | Efficacy as monotherapy limited. |
| Anti-VEGF/VEGFR therapies | Bevacizumab, Lenvatinib | VEGF and receptors | Inhibits angiogenesis by blocking VEGF interactions with its receptors. | Significant improvements in renal cell carcinoma outcomes. | Varies by agent: oral and IV formulations. | Common adverse reactions include hypertension and diarrhea. | Most patients develop resistance within 6-15 months. |
Open Research Questions
What mechanisms drive acquired resistance to pembrolizumab after initial response?
Understanding acquired resistance is essential for developing rational salvage strategies.
To what extent do PD-L1 expression, tumor mutational burden, and T cell-inflamed gene expression profile function as predictors of pembrolizumab response?
No single biomarker reliably identifies responders across histologies.
How does the gut microbiome modulate pembrolizumab efficacy and immune-related adverse event risk?
Preclinical data highlights microbiome's role in T cell responses to PD-1 blockade.
What is the mechanistic basis of immune-related adverse events?
Paradox of irAEs is complex, with higher response rates in patients developing them.
How does the optimal duration of pembrolizumab therapy vary by tumor type?
Current fixed-duration regimens may not be biologically rational.